GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (WBO:EVT) » Definitions » PB Ratio

Evotec SE (WBO:EVT) PB Ratio : 1.54 (As of May. 01, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Evotec SE PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-01), Evotec SE's share price is €9.715. Evotec SE's Book Value per Share for the quarter that ended in Dec. 2023 was €6.32. Hence, Evotec SE's PB Ratio of today is 1.54.

Good Sign:

Evotec SE stock PB Ratio (=1.52) is close to 10-year low of 1.46

The historical rank and industry rank for Evotec SE's PB Ratio or its related term are showing as below:

WBO:EVT' s PB Ratio Range Over the Past 10 Years
Min: 1.46   Med: 3.51   Max: 9.81
Current: 1.56

During the past 13 years, Evotec SE's highest PB Ratio was 9.81. The lowest was 1.46. And the median was 3.51.

WBO:EVT's PB Ratio is ranked better than
64.59% of 963 companies
in the Drug Manufacturers industry
Industry Median: 1.96 vs WBO:EVT: 1.56

During the past 12 months, Evotec SE's average Book Value Per Share Growth Rate was -5.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 12.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 21.50% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 22.90% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Evotec SE was 39.90% per year. The lowest was -25.60% per year. And the median was 8.95% per year.

Back to Basics: PB Ratio


Evotec SE PB Ratio Historical Data

The historical data trend for Evotec SE's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE PB Ratio Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.28 6.81 5.46 2.29 3.40

Evotec SE Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.59 2.29 3.12 2.94 3.40

Competitive Comparison of Evotec SE's PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's PB Ratio distribution charts can be found below:

* The bar in red indicates where Evotec SE's PB Ratio falls into.



Evotec SE PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Evotec SE's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=9.715/6.321
=1.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Evotec SE  (WBO:EVT) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Evotec SE PB Ratio Related Terms

Thank you for viewing the detailed overview of Evotec SE's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE (WBO:EVT) Business Description

Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Evotec SE (WBO:EVT) Headlines